Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 2, 2016, Pages 181-187

  Kappus, Natalie ^a   Weinstock Guttman, Bianca ^a   Hagemeier, Jesper ^a   Kennedy, Cheryl ^a   Melia, Rebecca ^a   Carl, Ellen ^a   Ramasamy, Deepa P ^a   Cherneva, Mariya ^a   Durfee, Jacqueline ^a   Bergsland, Niels ^a,b   Dwyer, Michael G ^a   Kolb, Channa ^a   Hojnacki, David ^a   Ramanathan, Murali ^a   Zivadinov, Robert ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GRAY MATTER; HEART VENTRICLE VOLUME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; ADOLESCENT; ADVERSE EFFECTS; AGE; AGED; ATROPHY; BRAIN; CARDIOVASCULAR DISEASES; COMPLICATION; COST OF ILLNESS; ETHNIC GROUP; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ATROPHY; BRAIN; CARDIOVASCULAR DISEASES; COST OF ILLNESS; ETHNIC GROUPS; FEMALE; GRAY MATTER; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958831822     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-310051     Document Type: Article

References (42)

1. Fox EJ. Immunopathology of multiple sclerosis. Neurology 2004;63:S3-7.
2. Pugliatti M, Harbo HF, Holmoy T, et al. Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008;188:34-40.
3. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-99.
4. Simon KC, van der Mei IA, Munger KL, et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1∗1501 on multiple sclerosis risk. Neurology 2010;74:1365-71.
5. Browne RW, Weinstock-Guttman B, Horakova D, et al. Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2014;85:859-64.
6. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-40.
7. Horakova D, Zivadinov R, Weinstock-Guttman B, et al. Environmental factors associated with disease progression after the first demyelinating event: results from the Multi-Center SET Study. PLoS ONE 2013;8:e53996.
8. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009;73:504-10.
9. Lunemann JD, Tintore M, Messmer B, et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010;67:159-69.
10. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71:306-14.
11. Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013;84:1186-91.
12. Karmon Y, Ramanathan M, Minagar A, et al. Arterial, venous and other vascular risk factors in multiple sclerosis. Neurol Res 2012;34:754-60.
13. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041-7.
14. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9.
15. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-50.
16. Christiansen CF, Christensen S, Farkas DK, et al. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 2010;35:267-74.
17. Hirst C, Swingler R, Compston DA, et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008;79:1016-21.
18. Fukuda H, Kitani M. Differences between treated and untreated hypertensive subjects in the extent of periventricular hyperintensities observed on brain MRI. Stroke 1995;26:1593-7.
19. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005;64:1704-11.
20. Almeida OP, Garrido GJ, Beer C, et al. Coronary heart disease is associated with regional grey matter volume loss: implications for cognitive function and behaviour. Intern Med J 2008;38:599-606.
21. Gianaros PJ, Greer PJ, Ryan CM, et al. Higher blood pressure predicts lower regional grey matter volume: ocnsequences on short-term information processing. Neuroimage 2006;31:754-65.
22. Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011;8:127.
23. Giubilei F, Antonini G, Di Legge S, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002;106:109-12.
24. Yancy CW, Sica DA. Cardiovascular disease in African Americans. J Clin Hypertens 2004;6:54-6.
25. Weinstock-Guttman B, Ramanathan M, Hashmi K, et al. Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology 2010;74:538-44.
26. O'Connor K, Weinstock-Guttman B, Carl E, et al. Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol 2012;259:637-44.
27. Zivadinov R, Marr K, Cutter G, et al. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011;77:138-44.
28. Dolic K, Weinstock-Guttman B, Marr K, et al. Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers. PLoS ONE 2011;6: e28062.
29. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59:331-9.
30. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-89.
31. Zivadinov R, Havrdova E, Bergsland N, et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831-41.
32. Ramasamy DP, Benedict R, Cox JL, et al. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci 2009;282:47-54.
33. Launer LJ, White LR, Petrovitch H, et al. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001;57:1447-52.
34. Regan C, Katona C, Walker Z, et al. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 2006;67:1357-62.
35. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69:1850-8.
36. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012;2012:367516.
37. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28:202-8.
38. Toda N, Ayajiki K, Okamura T. Obesity-induced cerebral hypoperfusion derived from endothelial dysfunction: one of the risk factors for Alzheimer's disease. Curr Alzheimer Res 2014;11:733-44.
39. Wang R, Fratiglioni L, Laveskog A, et al. Do cardiovascular risk factors explain the link between white matter hyperintensities and brain volumes in old age? A population-based study. Eur J Neurol 2014;21:1076-82.
40. Arikanoglu A, Shugaiv E, Tuzun E, et al. Impact of cigarette smoking on conversion from clinically isolated syndrome to clinically definite multiple sclerosis. Int J Neurosci 2013;123:476-9.
41. Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009;66:858-64.
42. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014;383:2213-21.